The company struggles to move the needle at the SITC meeting with an up-to-date cut of its first-line melanoma trial of NKTR-214 and Opdivo.
If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.
Split congressional control will result in more drug pricing talk, but don’t expect much action.
The abstract of the company’s Pivot-02 trial in first-line melanoma, due to be presented in full at SITC on Friday, looks disappointing.
An important test of Nektar’s cytokine agonist approaches, though some investors have already decided that Bristol-Myers Squibb was wrong to endorse it earlier this year.
Celgene’s Revlimid ranks as biopharma’s most contested blockbuster, with a huge spread in future sales forecasts, while drugs from Bristol-Myers Squibb and Sanofi also…
The price isn’t the real price, even in overseas markets. And if the US government is serious about drug price reductions, should it return to the idea of direct…
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Results from Tesaro, Sanofi, Novartis, Merck KGaA and others have come in thick and fast, but can any beat the entrenched leaders?